Search clinical trials for: Tumors that often express NY-ESO-1.

Total 67381 results

Hassane M. Zarour, MD
National Cancer Institute (NCI)

Completed

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

NY-ESO-1-expressing Tumors

United States
Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Tumors

United States
Athenex, Inc.

Withdrawn

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor
Shenzhen University General Hospital

Recruiting

Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

Advanced Soft-tissue Sarcoma

China
Ludwig Institute for Cancer Research
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; New York...

Completed

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Sarcoma | Esophageal Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer

United States
National Center for Tumor Diseases, Heidelberg
University Hospital Heidelberg

Completed

Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (CTLA4 NY-ESO-1)

Metastatic Melanoma

Germany
Ludwig Institute for Cancer Research

Completed

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

Prostate Cancer

Switzerland, Germany
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute

Completed

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Instituto de Investigação em Imunologia
Butantan Institute

Unknown

Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

Cancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.

Brazil
Ludwig Institute for Cancer Research
Krankenhaus Nordwest

Completed

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Melanoma | Sarcoma | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Transitional Cell Carcinoma | Prostate Cancer | Ovarian Carcinoma | Gastrointestinal Stromal Tumor (GIST)

Germany
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
TCRCure Biopharma Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of Stage III/IV Melanoma Patients

Melanoma

Switzerland
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)

Terminated

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Metastatic Cancer | Metastatic Melanoma

United States
Ludwig Institute for Cancer Research
NYU Langone Health

Completed

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

Tumors

United States
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Melanoma | Breast Cancer | Non-Small Cell Lung Cancer | Meningioma | Hepatocellular Cancer

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Ludwig Institute for Cancer Research

Completed

Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1

Neoplasms

Japan
Hadassah Medical Organization

Recruiting

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Sarcoma, Synovial | Ovary Cancer | Sarcoma,Soft Tissue | Melanoma Stage IV | Bladder Urothelial Carcinoma | Neuroblastoma, Metastatic

Israel
ImmunoFrontier, Inc.

Completed

Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

Esophageal Cancer

Japan
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
Case Comprehensive Cancer Center

Withdrawn

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Small Cell Lung Cancer | Non Small Cell Lung Cancer | Mesothelioma | Urothelial Cancer | Malignant Melanoma | Advanced Triple Negative Breast Cancer
Ludwig Institute for Cancer Research
Mie University

Completed

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Stomach Cancer | Breast Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer

Japan
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

Sarcoma

United States
Sun Yat-sen University
Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Recruiting

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Melanoma | Breast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Neuroblastoma | Bladder Carcinoma | Synovial Sarcoma | Esophagus Carcinoma | Other Metastatic Solid Cancers

China
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
GlaxoSmithKline

Completed

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1)

Neoplasms

United States
Penn State University

Withdrawn

A Vaccine Study for High Risk Cancers

Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma
Adaptimmune

Terminated

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Melanoma

United States
University of Arkansas

Completed

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

Multiple Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells Present

United States
University Health Network, Toronto
Takara Bio Inc.

Active, not recruiting

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Melanoma | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Liver Cancer | Synovial Sarcoma | NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients

Canada
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Pfizer; Oncovir, Inc.

Completed

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Melanoma

United States
GlaxoSmithKline
Merck Sharp & Dohme LLC

Withdrawn

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Neoplasms
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
Astellas Pharma Global Development, Inc.

Completed

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Ovarian Cancer | NSCLC | Solid Tumors | ESCC

United States
Guangzhou Institute of Respiratory Disease
Guangdong Xiangxue Precision Medical Technology Co., Ltd.; Xiangxue Life Science... and other collaborators

Unknown

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Lung Cancer, Nonsmall Cell, Recurrent

China
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Melanoma (Skin)

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, NY, USA

Terminated

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma

United States, Australia
Adaptimmune

Terminated

CT Antigen TCR-Engineered T Cells for Myeloma

Multiple Myeloma

United States
Fujian Cancer Hospital

Not yet recruiting

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Solid Tumors
Fiona Thistlethwaite
Karolinska University Hospital; University College London Hospitals; Erasmus... and other collaborators

Terminated

NY-ESO-1 T Cells in OG Cancer (ATTACK-OG)

Oesophageal Cancer

United Kingdom
Sun Yat-sen University
Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Active, not recruiting

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Soft Tissue Sarcoma | Bone Sarcoma

China
University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
ImmunoFrontier, Inc.

Completed

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Solid Tumor

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States

Search clinical trials for: Tumors that often express NY-ESO-1.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations